Zeit | Aktuelle Nachrichten | Rating | Leser | ||
---|---|---|---|---|---|
Fr | Molten Ventures - Making progress on its realisation agenda | 106 | Molten Ventures has recently completed the exits from Perkbox, Endomag and Graphcore. This translates into more than £70m realisation proceeds, which means Molten is on track to reach the £100m that... ► Artikel lesen | ||
Fr | discoverIE Group - FY25 earnings expectations maintained | 94 | discoverIE's Q125 trading update confirmed that underlying earnings expectations for FY25 are unchanged. While the Q125 revenue decline reflects the lower bookings environment in previous quarters,... ► Artikel lesen | ||
Fr | OSE Immunotherapeutics - Lusvertikimab shines in Phase II UC trial | 116 | OSE Immunotherapeutics' run of positive news continues with the announcement of encouraging data from the Phase II proof-of-concept CoTikiS study, evaluating Lusvertikimab as a novel treatment for ulcerative... ► Artikel lesen | ||
Do | Singapore Post - AGM update confirms review intentions | 123 | At the AGM management discussed the outcome of Singapore Post's strategic review and the recently announced strategic review into value creation options relating to the Australian logistics business.... ► Artikel lesen | ||
Mi | Alkane Resources - Kaiser a winner | 174 | Since our last update note on 20 May, Alkane has announced 1) the results of its scoping study on the Boda-Kaiser project, 2) FY24 production of 57,217oz Au at an all-in sustaining cost (AISC) guidance... ► Artikel lesen | ||
Mi | Primary Health Properties - Continuing dividend growth | 163 | Primary Health Properties' (PHP's) H124 results show continuing earnings and dividend growth, driven by rental income and underpinned by a low cost ratio and significantly fixed borrowing costs. With... ► Artikel lesen | ||
Mi | Mendus - Collaboration unveils path forward for ilixadencel | 132 | Mendus has announced a collaboration with Institut Bergonié, an established comprehensive cancer centre in France, to test ilixadencel in soft tissue sarcomas (STS) as part of an ongoing Phase I/II... ► Artikel lesen | ||
Mi | Centaur Media - BIG27 under way | 136 | Centaur's new mantra is 'Build, Improve, Grow' and this underpins its four-year management plan, BIG27, first unveiled in April. At its heart, BIG27 is predicated on leveraging Centaur's strong brands... ► Artikel lesen | ||
Di | Filtronic - Follow-on order from SpaceX | 156 | Filtronic has received a follow-on order from SpaceX worth $9m/£7.1m. This is the second order Filtronic has received since it signed the strategic partnership with SpaceX in April and results in the... ► Artikel lesen | ||
Mo | Baillie Gifford China Growth Trust - Economic transition driving growth opportunities | 112 | Baillie Gifford China Growth Trust (BGCG) focuses on innovative, growing Chinese companies with exposure to the massive opportunities generated by China's vast market, its positive long-term economic... ► Artikel lesen | ||
18.07. | Boku - Strong underlying revenue growth in H124 | 179 | In H124, digital wallets/account-to-account (A2A) adoption continued, with revenue growth of more than 50% y-o-y. Carrier billing revenues were robust with double-digit growth. The adjusted EBITDA margin... ► Artikel lesen | ||
18.07. | Baker Steel Resources Trust - Interim revaluations bring H124 NAV TR to c 5% | 150 | Baker Steel Resources Trust (BSRT) has released its end-June 2024 NAV (following the usual half-year valuation review of its unlisted holdings), posting a 1.8% NAV increase versus end-May 2024, which... ► Artikel lesen | ||
18.07. | Esker - Record Q2 bookings; FY24 outlook maintained | 163 | Esker reported Q224 year-on-year constant currency (cc) revenue growth of 14% and bookings annual recurring revenue (ARR) cc growth of 65%. Bookings more than doubled in the Americas, helped by a large... ► Artikel lesen | ||
17.07. | Substrate AI - AI venture builder | 118 | Substrate AI buys, builds and scales ventures with proprietary artificial intelligence (AI) to transform companies across a range of sectors into AI driven businesses. Its core technology, Serenity... ► Artikel lesen | ||
16.07. | Record PLC - Transitional year ahead | 124 | Record reported FY24 PBT of £12.9m, down 12% y-o-y and in line with our estimate of £12.8m. Underlying PBT was £14.8m, up 2% y-o-y on record assets under management (AUM), which grew 16.5% to $102.2bn.... ► Artikel lesen | ||
15.07. | Emerging markets revisited: A global opportunity (Video) | 127 | In a recent webinar, our expert panel explored the potential investment opportunities within key emerging market economies. Our panellists covered the impact of key secular themes on emerging markets... ► Artikel lesen | ||
11.07. | IRLAB Therapeutics - Anticipation builds as inflection points approach | 179 | IRLAB continued to progress its pipeline in Q224 and met key milestones, such as the clinical entry of IRL757 with non-dilutive backing from the Michael J Fox Foundation (MJFF) and the McQuade Center... ► Artikel lesen | ||
11.07. | Custodian Property Income REIT - Organic growth paying dividends | 168 | Custodian Property Income REIT's (CREI's) confidence in its organic growth outlook is reflected in accelerated, fully covered DPS growth. Reversionary income potential is strong and, with the occupier... ► Artikel lesen | ||
11.07. | Recce Pharmaceuticals - Taking a closer look at diabetic foot infections | 171 | We highlight the opportunity of topical RECCE® 327 (R327) to address diabetic foot infections (DFIs), which is the leading cause of limb morbidity in diabetic patients and an area of unmet need as currently... ► Artikel lesen | ||
10.07. | Revolution Beauty - Returning to profitability | 304 | Revolution Beauty's (REVB's) FY24 results demonstrated the new management team's progress on its updated strategy. Although revenue growth was relatively muted at c 2%, the streamlining of the brand... ► Artikel lesen | ||
10.07. | Kolibri Global Energy - New approach to drilling; potential share buyback | 202 | Kolibri Global Energy (KEI) has provided an update on operations and revised guidance. It now guides to FY24 revenue of US$57-62m and EBITDA of US$43-48m on average production of 3,200-3,700boepd. KEI... ► Artikel lesen | ||
10.07. | AFT Pharmaceuticals - Continued execution of footprint expansion | 198 | AFT Pharmaceuticals continues to make inroads in expanding its strategic market footprint. Most recently, it announced the entry into China with the distribution of Crystaderm (approved by Chinese regulators... ► Artikel lesen | ||
10.07. | Supermarket Income REIT - The next stage of growth | 215 | Supermarket Income REIT's (SUPR's) high-quality, omnichannel-focused portfolio is very well positioned to benefit from strong growth trends in the grocery sector. Moreover, with supermarket property... ► Artikel lesen | ||
10.07. | Immix Biopharma - US CAR-T trial commences patient dosing | 194 | Immix has announced that the first patient has been dosed in its Phase Ib NEXICART-2 trial of lead CAR-T asset NXC-201, which took place at lead study site, the Memorial Sloan Kettering Cancer Center.... ► Artikel lesen | ||
10.07. | Solid State - Record FY24; medium-term targets retained | 189 | Solid State is developing from a component manufacturer into a value-added electronics partner offering engineered solutions. Management expects this to drive additional growth and margin expansion... ► Artikel lesen |